*Applications will be reviewed on a rolling-basis.
A research opportunity is available at the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of the Center Director/ Controlled Substances Program (CSP) located in Silver Spring, Maryland.
The project will explore emerging public health and policy issues related to controlled substances (e.g., opioids and stimulants). The Controlled Substances Program works to promote public health by enabling appropriate access to controlled substances for medical use, while seeking to minimize risks associated with problematic use. Through scientific research, policy analysis, stakeholder engagement, interagency collaborations, and literature and news reviews, this project will help enhance CDER’s data-driven approach to combating the opioid epidemic.
Under the guidance of the mentor, the participant will learn how to use tools such as the Opioids Data Warehouse and conduct structured analysis of policy, news, and literature. Additionally, the participant will be included in meetings with CDER staff and other stakeholders and receive regular written and oral feedback on analysis and communications.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email.